EUDA puts a number on illegal CBD-to-THC conversion in Europe
Europe’s main drugs agency has attached a concrete enforcement number to a risk that much of the hemp and cannabinoid trade preferred to treat as background noise. In its European Drug Report 2026, published on 9 June, the European Union Drugs Agency said that in 2024 at least three illicit sites involved in producing THC or semi-synthetic cannabinoids were dismantled in Europe, with two in the Netherlands and one in Poland. In the same report, it said it has been asked in 2026 to assess CBD as a precursor for producing THC or other psychoactive cannabinoids.
That combination is the news. One part is an enforcement fact pattern, not a policy rumor. The other is a formal policy track, not a passing concern. For years, CBD in Europe has usually been argued over as a consumer product problem: food, cosmetics, wellness, medicines, claims, dosage, and retail format. The new signal shifts part of the debate upstream. It raises the possibility that some CBD will be examined not just as an ingredient sold to consumers, but as a chemical starting material that can be diverted into intoxicating products.
That matters now because the report is new and because the agency’s wording is unusually direct. This is not a retrospective academic paper or a national warning buried in a specialist bulletin. It is an EU-wide report package meant to guide the bloc’s view of drug markets and emerging risks. When that package says CBD use in semi-synthetic cannabinoid production is a cause of concern, and that a precursor assessment has been requested, it moves the issue from market chatter into the institutional record.
The immediate point is not that CBD has already been classified as a controlled precursor across the European Union. It has not. Nor does the report say that all CBD commerce is suspect. What it does say is more precise, and therefore more important. Europe now has confirmed illicit production sites tied to this conversion economy, and Brussels has opened the door to reviewing CBD through a precursor lens. That is enough to change how regulators, customs officials, police services, and supply-chain counterparties look at parts of the market.
A precursor review would move CBD from shelf rules to supply-chain control
To understand why this matters, it helps to separate plant extraction from chemical conversion. A conventional CBD business extracts or isolates cannabinoids from hemp and sells them as ingredients or finished products. A semi-synthetic cannabinoid business starts with one cannabinoid, often CBD, and chemically alters it into another compound. That is how products such as HHC entered the European market. The EUDA’s chapter on new psychoactive substances says these products are now being produced in Europe and that, by the end of 2025, 40 semi-synthetic cannabinoids had been identified on European drug markets.
CBD sits at the center of that shift because it is abundant, commercially available, and non-intoxicating in its usual form. Those features made it useful for lawful hemp and wellness markets. They also made it useful as feedstock for chemical conversion. In practical terms, the issue is no longer just whether a bottle, gummy, cosmetic, or vape liquid can be sold under consumer-product rules. It is whether part of the bulk CBD stream can be redirected into making psychoactive cannabinoids that sit outside or ahead of existing product controls.
That is where precursor policy comes in. In ordinary language, a drug precursor is a substance that can be used to manufacture an illicit drug. Precursor controls are not product-label rules. They are supply-chain controls aimed at substances before they become the finished drug. A precursor assessment is the technical exercise that examines whether a substance is being used this way and whether EU-wide restrictions are justified. If controls follow, the practical effects can include tighter monitoring of trade, stronger reporting obligations for suspicious orders, and more attention to who is buying what, in what volume, and for what declared use.
This is not a theoretical machinery. Earlier in 2026, EUDA published its first EU-level precursor assessment reports. In April, the European Commission followed those assessments by putting nine substances under EU control, with a transition period for economic operators. The institutional lesson is clear enough: precursor review is now an active route to EU action. That is why CBD’s appearance on that track matters even before any final decision is made.
The significance becomes sharper when set against CBD’s long legal ambiguity in Europe. EUDA’s own commercial-cannabis guidance shows that CBD products have sat across several rulebooks at once. Depending on the product and the claim, CBD may fall into medicines law, cosmetics law, food law, novel food authorization, or general consumer regulation. The legal position also changed after the Kanavape ruling, which established that lawfully produced CBD is not treated as a narcotic simply because it comes from the whole cannabis plant. That removed one obstacle, but it did not create a single market rule for all CBD products. Businesses have therefore spent years managing category risk at the retail end. A precursor review shifts attention to what happens before retail, where the relevant questions are origin, concentration, customer type, and potential diversion.
The first businesses in scope are the ones moving bulk extract across borders
The most exposed operators are not necessarily the ones a casual consumer sees. They are the firms that sit in the middle of the supply chain: hemp extractors, isolate producers, ingredient brokers, private-label manufacturers, and traders moving bulk material between member states. If authorities start to treat some CBD commerce as a diversion risk, those businesses will be the first place regulators look. The reason is simple. Bulk ingredients move in larger volumes, change hands several times, and can be repurposed before reaching any final retail format.
White-label manufacturing is an obvious pressure point. Much of Europe’s cannabinoid market is built on contract production, relabeling, and rapid product switching. A factory may produce compliant CBD goods for one client while another customer wants a different cannabinoid profile, a vape formulation, or a market-specific product line that sits close to legal boundaries. That does not mean the manufacturer is engaged in illicit conversion. It does mean regulators may start looking harder at whether the underlying supply chain can distinguish clearly between straightforward CBD commerce and material destined for chemical alteration.
Brands exposed to HHC-style demand also have reason to pay attention, even if they never handled conversion chemistry themselves. EUDA’s new psychoactive substances chapter describes a market that evolved from CBD-derived compounds into a broader family of semi-synthetic cannabinoids. Once that market exists, the enforcement lens widens. Authorities no longer need to view each new cannabinoid as a separate novelty. They can look instead at the common starting material and at the commercial channels that repeatedly connect legal hemp extraction to intoxicating end products.
Cross-border trade is where this could become visible fastest. Europe already has a fragmented CBD market in which one member state’s tolerated product can still face difficulties in another because product categories, enforcement priorities, and retail rules differ. A precursor frame would add another layer. Customs and police do not need a final harmonized view of every finished product to take interest in a bulk substance that may be diverted into illegal manufacture. Even before any formal EU-wide control, the existence of an assessment process can make counterparties more cautious, add friction to warehousing and transport, and increase the importance of transaction records and end-use explanations.
Medical businesses are not the main target here, but they are not fully outside the picture either. Europe’s regulated medical cannabis channels rely on more formal product standards and clearer therapeutic pathways than the consumer CBD market. Even so, ingredient sourcing and contract manufacturing networks can overlap. If scrutiny intensifies around bulk cannabinoids, medical supply chains may face stronger demands to separate pharmaceutical-grade operations from the wider hemp extract economy. That is not the same as saying patient access changes tomorrow. It is a reminder that upstream controls often reach further than the retail categories that dominate public debate.
The broader market signal is that Europe is starting to regulate the conversion chain, not just the finished molecule. That is the practical meaning of the figure buried in the report. At least three dismantled sites in one year is not a giant industrial count, but it is enough to show that the issue is domestic as well as imported. Europe is not only seeing finished semi-synthetic products arrive from elsewhere. It is seeing production capacity on its own territory.
Europe is deciding whether CBD remains a hemp ingredient or becomes a watched chemical input
The uncertainty now is about scope and speed. A request to assess CBD as a precursor does not predetermine the outcome. Authorities could conclude that the evidence supports controls, or they could decide the risk can be handled in a narrower way. If controls are proposed, the final shape would matter enormously. The question is not just whether CBD is named, but which forms, concentrations, transaction patterns, or commercial contexts fall within that decision. The Commission’s recent use of transition periods for newly controlled precursors suggests that, if action comes, there may be some implementation runway. It does not remove the commercial significance of the review itself.
The harder point for the industry is that the old argument is losing ground. For a long time, CBD businesses could plausibly treat their main challenge as one of consumer-product classification. Was the item a food, a cosmetic, a medicinal product, or something sold in a wellness grey zone? That argument is still real. But it no longer captures the whole regulatory risk. Once a substance is discussed as a possible precursor, the state stops looking only at what is on the shelf and starts looking at what moved through the warehouse, who bought it, and what it could become.
There is also a political logic to this shift. Chasing finished semi-synthetic cannabinoids one by one is slow. Markets can rename, reformulate, or replace a substance faster than legislation can catch up. A precursor approach targets the bottleneck instead. That does not solve every enforcement problem, and it may create difficult boundary questions for lawful hemp commerce. But from an institutional perspective it is a cleaner intervention point. If policymakers believe the same CBD stream feeds both ordinary retail products and illicit conversion, pressure to act upstream becomes much easier to justify.
That leaves Europe at a more consequential dividing line than the familiar debates over CBD packaging, wellness claims, or boutique retail formats. The bloc is deciding whether CBD remains mainly a hemp ingredient governed by product law, or whether part of it is now a watched chemical input governed by diversion risk. If the second view gains ground, the center of gravity will move away from marketing language and toward traceability, transaction visibility, and industrial scrutiny. For a sector that grew up around the idea that CBD was the non-problem cannabinoid, that is a material change in how the market will be judged.